Our research has therefore identified SHP2 as a novel driver of psoriasis pathogenesis and suggested SHP2 inhibition as a promising therapeutic approach for the treatment of autoimmune diseases, such as psoriasis. This evidence concerns the gene PTPN11 and autoimmune disease.